Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 2Sarcoma 2Melanoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Skin Neoplasms 1Resectable Hepatocellular Carcinoma 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Ichthyosis, X-Linked 1Glioma 1

Interventions

Etoposide 79Carboplatin 67Cisplatin 58durvalumab 30Irinotecan 29Radiotherapy 27atezolizumab 23Topotecan 21anlotinib 19Nivolumab 15Drug Therapy 15Radiosurgery 14Paclitaxel 13Gemcitabine 13apatinib 12toripalimab 10Platinum 10Docetaxel 10tislelizumab 9Temozolomide 9PM 01183 9pembrolizumab 7olaparib 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Bevacizumab 7Albumin-Bound Paclitaxel 7irinotecan sucrosofate 6Counseling 6sintilimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Carcinoma × ADI PEG20 × Clear all
NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Washington University School of Medicine

Phase 1/2 Active not recruiting
31 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01266018 2022-10-25

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Ludwig Institute for Cancer Research

Phase 2 Terminated
22 enrolled 14 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡